1. Home
  2. Labeler Index
  3. Nucare Pharmaceuticals,inc.
  4. 68071-4495
  5. Product Images: Carvedilol

Product Images Carvedilol

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Carvedilol NDC 68071-4495 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

68071 4495 8

68071 4495 8

NuCare Pharmaceuticals, Inc. provides Carvedilol tablets in the strength of 12.5mg. The packaging contains 180 tablets. Each film-coated tablet contains Carvedilol USP 12.5mg and has 'E' on one side and '03' on the other side. The tablets are oval-shaped and white/off-white in color. The medication is available only through a doctor's prescription. Patients may experience side effects and are encouraged to report them to the FDA. NuCare Pharmaceuticals, Inc. warns to keep the medication out of reach of children and store it at a temperature between 68-77°F.*

Figure 1. Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol fig1

Figure 1. Survival Analysis for COPERNICUS (Intent-to-Treat) - carvedilol fig1

Figure 2. Effects on Mortality for Subgroups in COPERNICUS - carvedilol fig2

Figure 2. Effects on Mortality for Subgroups in COPERNICUS - carvedilol fig2

The text provides a figure (Figure 2) showing the effects on mortality for subgroups in COPERNICUS. The subgroups are categorized by gender (men and women), age (less than 65 or equal and above to 65), race (black or non-black), diabetes status (diabetic or non-diabetic), heart disease type (ischemic or non-ischemic), heart rate (<70 or above), blood pressure (BP), and use of spironolactone. The hazard ratio is plotted on the y-axis and ranges from 0 to 20. There is no information available regarding the values of hazard ratio or what the figure represents.*

Figure 3. Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol fig3

Figure 3. Survival Analysis for CAPRICORN (Intent-to-Treat) - carvedilol fig3

Figure 4. Effects on Mortality for Subgroups in CAPRICORN - carvedilol fig4

Figure 4. Effects on Mortality for Subgroups in CAPRICORN - carvedilol fig4

Chemical Structure - carvedilol str

Chemical Structure - carvedilol str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.